New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics
December 2016 |
Welcome to the December 2016 issue of PharmSource PERISCOPE
This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.
Enjoy the December issue, and happy holidays!
PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity
Lead Type | November 2016 | YTD 2016 |
---|---|---|
Early Development | 110 | 1296 |
Late Development | 117 | 1304 |
Biologic | 114 | 1150 |
Small Molecule | 251 | 2820 |
Parenteral | 118 | 1248 |
Oral | 88 | 1091 |
New Financings | 62 | 854 |
Total Drug Leads | 338 | 4101 |
Total Device & Diagnostic Leads |
132 | 1544 |
*Total leads include acquisitions/alliances, company acquisition/alliances and events.
Pipeline Tip
Amryt Pharma plans to initiate a Phase III trial with episalvan for the treatment of epidermolysis bullosa in early 2017:
- Therapeutic Area: Dermatology
- Dosage Form: Semi-solid – Sterile
- API: Botanical
Get deeper information about the likely upcoming needs of Amryt, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.
Biosimilars: Like Ryan Reynolds and Ryan Gosling
by Brooke Wilson, Senior Research Analyst
The FDA describes a biosimilar as a biological product that is approved based on a showing that it is highly similar to an FDA-approved biological product, known as a reference product, that has no clinically meaningful differences in terms of safety and effectiveness from the reference product. Only minor differences in clinically inactive components are allowable in biosimilar products. Arguably very similar to the two Canadians featured in the title.
As of December 5th, 2016, the EMA had approved 23 biosimilars. The first was in 2006, Omnitrope, produced by Sandoz. In contrast the FDA has only approved… read on
Follow the Money to
Bio/Pharmaceutical Opportunities
Spotlight on Synthetic Biologics, Inc.
Synthetic Biologics, formerly known as Adeona Pharmaceuticals, is a U.S. public bio/pharmaceutical company that develops late-stage, orally available, small molecule drugs for the treatment of neurological and fibrotic diseases. They plan to raise $25 million in a secondary public offering.
What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to fund the clinical development of its pipeline, including… read on
Follow the Money to
Medical Device & Diagnostic Opportunities
Spotlight on Genalyte Inc.
Genalyte is a U.S. private company that develops and manufactures next-generation multiplexing instruments and apparatus. They raised $36 million in a completion of a Series D venture capital investment.
What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support the development and regulatory approval of the Maverick Detection System… read on
Bio/Pharma Sponsor Spending on In-house Manufacturing Capacity Soars

PharmSource Lead Sheet
The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.
Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.
See for yourself how this resource can be a vital tool for building your brand and growing your market share.
To request a test-drive today, contact Nathaniel Celentano at info@pharmsource.com / 1-703-383-4903 (ET USA).